Cargando…

CS-12 IDH-1 MUTANT GLIOMA IN BROTHER AND SISTER, ONSET AT AGE OF 30s

A 38-year-old man consulted with our neurosurgery group at University of Fukui hospital, due to tonic-clonic seizures. An MRI revealed a non-enhanced intra-axial tumor at the left frontal lobe. CT showed no calcification in the tumor. The tumor was removed by awake brain surgery. The pathological sp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitai, Ryuhei, Yamauchi, Takahiro, Neishi, Hiroyuki, Isozaki, Makoto, Tsunetoshi, Kenzo, Matsuda, Ken, Arishima, Hidetaka, Kodera, Toshiaki, Kikuta, Ken-ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213226/
http://dx.doi.org/10.1093/noajnl/vdz039.182
Descripción
Sumario:A 38-year-old man consulted with our neurosurgery group at University of Fukui hospital, due to tonic-clonic seizures. An MRI revealed a non-enhanced intra-axial tumor at the left frontal lobe. CT showed no calcification in the tumor. The tumor was removed by awake brain surgery. The pathological specimen was diagnosed as a diffuse astrocytoma with IDH-mutant. Immunohistochemical staining and DNA sequencing confirmed a R132H mutation at IDH-1. Telomerase Reverse Transcriptase (TERT) promoter mutation and 1p 19q codeletion was not evident. Four years later, his sister, a 40-year-old woman, had an MRI as a routine medical check that found a right frontal tumor at the mirror site of her brother’s tumor, and with identical radiological findings. The tumor was completely removed. The specimen revealed oligodendrocytoma, with mutant IDH and 1p/19q co-deleted. DNA sequencing showed also R132H at IDH-1. TERT promoter mutation was evident at C228T, which is a surrogate marker for oligodendroglioma. IDH-mutant astrocytoma and oligodendroglioma in siblings; and germline mutation of IDH have not been reported. However, the respective incidences of astrocytoma and oligodendroglioma are 0.55/100,000/year and 0.26/100,000/year according to United State statistics, which indicates that merely coincidental occurrence of these tumors is extremely unlikely. A trigger for IDH mutation that runs in rare families could warrant whole-genome sequencing.